Skip to main content
Uncategorized

Kymos launches an innovative R&D division in biotechnology at the Barcelona Science Park

By 13 de June de 2012November 18th, 2020No Comments
< Back to news
Kymos' s management team
 13.06.2012

Kymos launches an innovative R&D division in biotechnology at the Barcelona Science Park

, a company providing scientific-technical services has opened a new immunology laboratory at the Barcelona Science Park that has been successfully audited for GLP compliance by regulatory health authorities. Kymos currently has three other lab facilities at the PCB in the field on bioanalysis and analytical development and quality control. This project has been made possible thanks to an agreement reached between Kymos and the multinational biotech company Ipsen in December of 2011. As a result of this agreement, Kymos took on a team a team of scientists, equipment and know-how from the former R&D site of the multinational in Spain .


The new biotech division of Kymos will provide full services for innovative biologics, biosimilars and vaccines. Kymos will officially present its innovative R&D area in the field of biomolecules to the scientific community at the , which will be held from 18 to 21 June at the Boston Convention & Exhibition Center, in Boston (Massachusetts, US), and that will be attended by the president of the Generalitat of Catalunya, Artur Mas.

«Despite the short time ago that we started this business, the prospects are very good. We have managed to arise the interest of major pharmaceutical companies within and outside the country and signed the first contracts “- says Joan Puig, Director General for Strategic Development at Kymos.

Kymos is a CRO (Contract Research Organization) based at the Barcelona Science Park , founded in 2001 by a group of professionals with over 10 years experience at the pharmaceutical sector within the R&D area. The company focuses its activity on the development of bioanalysis for the chemical-pharmaceutical, biotechnological, veterinary, cosmetic, and nutraceutical sectors. The company has forecasted a turnover of nearly 4 million Euros for 2012, employs 45 professionals, has a direct presence in Portugal, Italy and Switzerland, and has a portfolio of over 80 clients, including the most important pharmaceutical companies both in Spain and in other countries.

Strategic agreement with ACCIÓ

To consolidate its internationalization plan, Kymos just signed a collaboration agreement with ACC1Ó, whereby it will start commercial activities in the French and US markets. Kymos, that currently covers the markets in Spain, Portugal, Italy and Switzerland, opened last year a permanent representation office in Italy, having successfully achieved a fast introduction in this market, with results that exceed its original expectations.

«The agreement reached with ACC1Ó allow us to accelerate international expansion and to cope with the crisis that is hitting the pharmaceutical industry so hard, especially in Spain “- says Joan Puig.